logo

NEO

Neogenomics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 0
consensus rating "Strong Buy"
Revenue Beats Expectation
EPS Beats Expectation

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About NEO

Neogenomics, Inc.

A leading provider of oncology testing and global contract research services

Life Science Tools and Services
10/29/1998
12/10/2012
NASDAQ Stock Exchange
2200
12-31
Common stock
9490 NeoGenomics Way, Fort Myers, Florida, 33912
--
Neogenomics, Inc., was incorporated in Nevada on October 29, 1988. Specializing in cancer genetics testing and information services, the company provides physicians with one of the most comprehensive oncology-centric testing menus in the world to help them diagnose and treat cancer. The Company's Drug Services Division provides clinical trials and drug development services to pharmaceutical clients. On October 29, 1998, the parent company was incorporated in Nevada as American Communications Enterprises, Inc., and the parent company changed its name to Neogenomics, Inc., on December 14, 2001.

Company Financials

EPS

NEO has released its 2024 Q4 earnings. EPS was reported at 0.04, versus the expected 0.03, beating expectations. The chart below visualizes how NEO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

NEO has released its 2024 Q4 earnings report, with revenue of 172.00M, reflecting a YoY change of 10.57%, and net profit of -15.32M, showing a YoY change of -6.97%. The Sankey diagram below clearly presents NEO’s revenue sources and cost distribution.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime